ANAPTYSBIO, INC. (ANAB) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
52/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinANAB / S&P 82.56% / 15.20% |
LoseANAB / S&P ANAB unavailable / 15.00% |
LoseANAB / S&P ANAB unavailable / 50.40% |
| 2026-Q12/3 |
WinANAB / S&P 14.40% / -4.33% |
WinANAB / S&P 107.73% / 11.30% |
LoseANAB / S&P -79.96% / 27.70% |
| 2025-Q42/3 |
WinANAB / S&P 58.33% / 2.65% |
WinANAB / S&P 157.01% / 9.00% |
LoseANAB / S&P -92.23% / 13.40% |
| 2025-Q32/3 |
WinANAB / S&P 37.93% / 8.12% |
WinANAB / S&P 196.42% / 4.61% |
LoseANAB / S&P -54.61% / 13.45% |
| 2025-Q22/3 |
WinANAB / S&P 19.42% / 10.94% |
WinANAB / S&P 304.17% / 4.83% |
LoseANAB / S&P -30.39% / 10.63% |
| 2025-Q12/3 |
WinANAB / S&P 40.41% / -4.27% |
WinANAB / S&P 387.20% / 4.98% |
LoseANAB / S&P -21.99% / 10.57% |
| 2024-Q41/3 |
LoseANAB / S&P -60.48% / 2.41% |
WinANAB / S&P 432.03% / 5.25% |
LoseANAB / S&P -15.30% / 6.15% |
| 2024-Q33/3 |
WinANAB / S&P 33.68% / 5.89% |
WinANAB / S&P 282.17% / 5.89% |
WinANAB / S&P 12.18% / 6.11% |
| 2024-Q23/3 |
WinANAB / S&P 11.28% / 4.28% |
WinANAB / S&P 135.59% / 5.38% |
WinANAB / S&P 22.35% / 5.12% |
| 2024-Q12/3 |
LoseANAB / S&P 5.14% / 10.56% |
WinANAB / S&P 114.78% / 5.71% |
WinANAB / S&P 26.86% / 5.59% |
| 2023-Q43/3 |
WinANAB / S&P 19.27% / 11.69% |
WinANAB / S&P 66.78% / 6.81% |
WinANAB / S&P 33.04% / 7.78% |
| 2023-Q32/3 |
LoseANAB / S&P -11.70% / -3.27% |
WinANAB / S&P 233.18% / 7.52% |
WinANAB / S&P 12.22% / -5.03% |
| 2023-Q21/3 |
LoseANAB / S&P -6.53% / 8.74% |
LoseANAB / S&P -46.30% / 9.50% |
WinANAB / S&P 33.42% / -8.57% |
| 2023-Q11/3 |
LoseANAB / S&P -29.78% / 7.50% |
LoseANAB / S&P -79.79% / 10.77% |
WinANAB / S&P 75.36% / -15.69% |
| 2022-Q42/3 |
WinANAB / S&P 21.48% / 7.56% |
LoseANAB / S&P -83.72% / 11.88% |
WinANAB / S&P 116.59% / -17.99% |
| 2022-Q31/3 |
WinANAB / S&P 25.67% / -4.88% |
LoseANAB / S&P -96.32% / 13.47% |
LoseANAB / S&P -1658.06% / -1.41% |
| 2022-Q21/3 |
LoseANAB / S&P -17.95% / -16.10% |
LoseANAB / S&P -76.22% / 13.71% |
WinANAB / S&P 1115.62% / 11.04% |
| 2022-Q11/3 |
LoseANAB / S&P -28.81% / -4.60% |
LoseANAB / S&P -25.75% / 15.97% |
WinANAB / S&P 153.21% / 42.23% |
| 2021-Q41/3 |
WinANAB / S&P 28.13% / 11.03% |
LoseANAB / S&P -15.77% / 15.00% |
LoseANAB / S&P ANAB unavailable / 96.40% |
| 2021-Q32/3 |
WinANAB / S&P 4.59% / 0.58% |
WinANAB / S&P 578.69% / 10.77% |
LoseANAB / S&P ANAB unavailable / 69.42% |
| 2021-Q22/3 |
WinANAB / S&P 20.32% / 8.55% |
WinANAB / S&P 462.63% / 6.58% |
LoseANAB / S&P ANAB unavailable / 51.81% |
| 2021-Q11/3 |
LoseANAB / S&P 0.23% / 6.17% |
WinANAB / S&P 209.77% / -1.06% |
LoseANAB / S&P ANAB unavailable / 7.39% |
| 2020-Q42/3 |
WinANAB / S&P 45.76% / 12.15% |
WinANAB / S&P 837.50% / -3.72% |
LoseANAB / S&P ANAB unavailable / -33.42% |
| 2020-Q31/3 |
LoseANAB / S&P -33.97% / 8.93% |
WinANAB / S&P 260.00% / -2.04% |
LoseANAB / S&P ANAB unavailable / -27.10% |
| 2020-Q22/3 |
WinANAB / S&P 58.10% / 20.54% |
WinANAB / S&P 80.00% / -0.46% |
LoseANAB / S&P ANAB unavailable / -27.11% |
| 2020-Q12/3 |
WinANAB / S&P -13.05% / -19.60% |
WinANAB / S&P 360.00% / 3.47% |
LoseANAB / S&P ANAB unavailable / -14.75% |
| 2019-Q41/3 |
LoseANAB / S&P -53.56% / 9.07% |
WinANAB / S&P 60.00% / 5.36% |
LoseANAB / S&P ANAB unavailable / 2.99% |
| 2019-Q30/3 |
LoseANAB / S&P -37.98% / 1.70% |
LoseANAB / S&P -37.50% / 5.02% |
LoseANAB / S&P ANAB unavailable / 0.21% |
| 2019-Q21/3 |
LoseANAB / S&P -22.77% / 4.30% |
WinANAB / S&P 233.33% / 6.64% |
LoseANAB / S&P ANAB unavailable / 8.65% |
| 2019-Q11/3 |
WinANAB / S&P 14.52% / 13.65% |
LoseANAB / S&P -50.00% / 8.12% |
LoseANAB / S&P ANAB unavailable / 14.29% |
| 2018-Q40/3 |
LoseANAB / S&P -36.06% / -13.52% |
LoseANAB / S&P -50.00% / 9.05% |
LoseANAB / S&P ANAB unavailable / 18.23% |
| 2018-Q31/3 |
WinANAB / S&P 40.44% / 7.71% |
LoseANAB / S&P -17.98% / 10.21% |
LoseANAB / S&P ANAB unavailable / 19.06% |
| 2018-Q20/3 |
LoseANAB / S&P -31.74% / 3.43% |
LoseANAB / S&P -76.87% / 9.03% |
LoseANAB / S&P ANAB unavailable / 14.46% |
| 2018-Q11/3 |
WinANAB / S&P 3.34% / -0.76% |
LoseANAB / S&P -15.38% / 7.68% |
LoseANAB / S&P ANAB unavailable / 12.46% |
| 2017-Q41/3 |
WinANAB / S&P 188.18% / 6.64% |
LoseANAB / S&P -40.06% / 7.03% |
LoseANAB / S&P ANAB unavailable / 13.82% |
| 2017-Q31/3 |
WinANAB / S&P 46.05% / 4.48% |
LoseANAB / S&P ANAB unavailable / 5.68% |
LoseANAB / S&P ANAB unavailable / 17.57% |
| 2017-Q20/3 |
LoseANAB / S&P -13.77% / 3.09% |
LoseANAB / S&P ANAB unavailable / 4.83% |
LoseANAB / S&P ANAB unavailable / 17.74% |
| 2017-Q10/3 |
LoseANAB / S&P ANAB unavailable / 6.07% |
LoseANAB / S&P ANAB unavailable / 3.67% |
LoseANAB / S&P ANAB unavailable / 13.32% |
| 2016-Q40/3 |
LoseANAB / S&P ANAB unavailable / 3.82% |
LoseANAB / S&P ANAB unavailable / 2.09% |
LoseANAB / S&P ANAB unavailable / 7.05% |
| 2016-Q30/3 |
LoseANAB / S&P ANAB unavailable / 3.85% |
LoseANAB / S&P ANAB unavailable / 0.20% |
LoseANAB / S&P ANAB unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ANAB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 322.70% | 20.78% |
| Annualized return | 322.70% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ANAB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 231.41% | 83.14% |
| Annualized return | 27.08% | 12.86% |
10Y · 2017-01-26 to 2026-08-27
| Metric | ANAB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 405.50% | 319.30% |
| Annualized return | 17.59% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |